PointState Capital’s Immunogen Inc IMGN Stock Holding History

PointState Capital’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,673,799	Closed	-$17.6M	–	204
2018 Q1	$17.6M	Buy	+1,673,799	New	+$16.5M	0.19%	79

Other funds holding IMGN

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PointState Capital's IMGN Position: Q2 2018 in Review

PointState Capital sold out of Immunogen Inc (IMGN) in Q2 2018, closing a stake of 1,673,799 shares — an estimated $17.6M sold.

PointState Capital first reported a position in IMGN in Q1 2018 and held it in 1 quarter. The position peaked at $17.6M in Q1 2018. 198 funds tracked by Wall St. Rank hold IMGN as of Q2 2018.

PointState Capital reported no remaining Immunogen Inc position as of Q2 2018 after selling out during the quarter.
PointState Capital sold 1,673,799 Immunogen Inc shares in Q2 2018, an estimated $17.6M.
PointState Capital first reported a position in Immunogen Inc in Q1 2018 and held it in 1 quarter.
PointState Capital's Immunogen Inc position peaked at $17.6M in Q1 2018.
198 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2018.

Based on PointState Capital's 13F filing for Q2 2018, filed 14 Aug 2018.